Immunity Period After One Dose of Yellow Fever Vaccine in Adults and Children (Paraiba Study)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE4

Total Enrollment

4761 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-07-31

Study Completion Date

2027-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study main objective is to assess the immune status of children and adults who have never vaccinated, they will receive the first dose of 17DD yellow fever vaccine provided by the study and will be monitored for 10 years. Depending on the results of the analyzed of the data, the period of monitoring may be extended.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Study of Immunity Duration of Yellow Fever Vaccine in Military

NCT03338231

Yellow Fever Vaccine

COMPLETED

Duration of Immunity 10 Years After a Dose-response Study With Yellow Fever Vaccine - Complementary Study

NCT04416477

Yellow Fever Vaccine

UNKNOWN

Study of the Transmission-Blocking Vaccine Pfs230D1-EPA/Matrix-M Against Malaria in Adults in Mali

NCT05135273

Malaria,Falciparum

COMPLETED PHASE1

Pan-Malaria Transmission-Blocking Vaccine AnAPN1

NCT05905432

Malaria

COMPLETED PHASE1

Adenovirus Type 35 Based Circumsporozoite Malaria Vaccine in Burkina Faso

NCT01018459

Malaria

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a Phase IV study cohort, uncontrolled, composed of two segments: children and healthy adults. It will be included 2756 children and 2005 adults, evaluated initially in six different times (before vaccination, 30-45 days, 1 year, 4 years, 7 years and 10 years after vaccination). The Paraiba state was selected for the study because in this region there are no yellow fever virus dissemination and therefore no NIP recommendation for people's routine vaccination. However, the NIP indicate yellow fever vaccination for individuals who are moving to areas with virus circulation. The study will take place in six (6) Basic Health Units of three (3) municipalities (2 units per municipality) in the state of Paraíba. The selected municipalities are: Alhandra, Caaporã and Conde. The study target population consisted of healthy children and adults of both sexes. Children must be between 9 months and 4 years,11months and 29 days; adults between 18 and 50 years. It will be eligible for the study, people who have never received the yellow fever vaccine checked in vaccine design and history and who agree to participate. Not be included participants with any contraindication to vaccination against yellow fever and individuals who previously moved to risk areas for extended periods.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Yellow Fever Vaccine Immunity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

naive children and adults for yellow fever vaccine

both sexes; ages between 9 months and 4 years, 11 months and 29 days old; 18 years to 50 years old

Group Type OTHER

yellow fever vaccine

Intervention Type BIOLOGICAL

yellow fever vaccination in naive individuals who leaves in a state where this type of vaccination is not recommendated

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

yellow fever vaccine

yellow fever vaccination in naive individuals who leaves in a state where this type of vaccination is not recommendated

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Ability to understand and sign the Informed Consent Term
2. Acceptance in participate on the study after reading, understanding and signed the Informed Consent Term
3. Participants of both sexes aged 9-4 years, 11 months and 29 days, after it was provided they have not received or have to receive the MMR or Tetraviral vaccine within 30 days or less.
4. Healthy adults of both sexes aged between 18 and 50 years since they have not received or have to receive the MMR or Tetraviral vaccine within 30 days or less.
5. Residence fixed in the municipality where the Basic Health Unit will held vaccination and collection of biological material samples (blood) for the study at the time of participant enrollment.
6. Availability to follow the proposed activities throughout the study period.
7. Agreement to provide name, address, telephone number and other information for personal contact is possible, if necessary (for example, event of failure to visit scheduled for follow-up).
8. Availability to follow the study protocol.
9. Acceptance for serological testing for HIV.
10. In adult women, it will be conduct pregnancy test (TIG).

Exclusion Criteria

12. Physical examination of screening with no significant clinical changes.

1. Previous vaccination against yellow fever.
2. Presumed or confirmed pregnancy at any stage.
3. Women who are breastfeeding.
4. People in use, or have made use of immunosuppressants medicines.
5. People with personal history of anaphylactic reaction to food, drugs or vaccines.
6. People with personal history of allergy to egg ,erythromycin, kanamycin or gelatin.
7. People with autoimmune diseases.
8. Individuals seropositive for HIV.
9. People with thymic disease history, such as thymoma, myasthenia due to thymectomy and thymoma.
10. People who have received immunoglobulin, blood transfusions or derivatives in the last 60 days.
11. People who have received live virus vaccines or against cholera in the last 30 days, or who plan to receive them within 30 days after vaccination against yellow fever.
12. Individuals who have resided in an endemic area.
13. People with acute febrile disease and a compromised general health.
14. People immunosuppressed by disease (eg, cancer, AIDS, HIV infection with impaired immunity, etc.) or drugs (immunosuppressive drugs, radiotherapy, etc.).

Minimum Eligible Age

9 Months

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes